News & Publications
News
Oct 3, 2024
HOPO Therapeutics awarded BARDA contract of up to $226 million
Nov 2, 2023
HOPO Therapeutics jointly awarded $1.78M ARPA-E Grant
Jun 9, 2023
Phase 1 Clinical Trial of HOPO 14-1 Now Recruiting
Jun 8, 2023
CEO Julian Rees named 2023 Activate Fellow
May 15, 2023
Launch of Phase 1 Clinical Trial for HOPO 14-1
Dec 16, 2022
Poets & Quants names HOPO Therapeutics a 2022 Most Disruptive MBA Startup
Publications
Proceedings of the National Academy of Sciences • Apr 2021
Genome-wide toxicogenomic study of the lanthanides sheds light on the selective toxicity mechanisms associated with critical materials
Roger M. Pallares, David Faulkner, Dahlia D. An, Solene Hebert, Alex Loguinov, Michael Proctor, Jonathan A. Villalobos, Kathleen A. Bjornstad, Chris J. Rosen, Christopher Vulpe, Rebecca J. Abergel
Nature • Feb 2021
Structural and spectroscopic characterization of an einsteinium complex
Korey P. Carter, Katherine M. Shield, Kurt F. Smith, Zachary R. Jones, Jennifer N. Wacker, Leticia Arnedo-Sanchez, Tracy M. Mattox, Liane M. Moreau, Karah E. Knope, Stosh A. Kozimor, Corwin H. Booth, Rebecca J. Abergel
Scientific Reports • Mar 2018
Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents
Julian A. Rees, Gauthier J.-P. Deblonde, Dahlia D. An, Camille Ansoborlo, Stacey S. Gauny, Rebecca J. Abergel
New Journal of Chemistry • Feb 2018
Toxic heavy metal – Pb, Cd, Sn – complexation by the octadentate hydroxypyridinonate ligand archetype 3,4,3-LI(1,2-HOPO)
Gauthier J.P. Deblonde, Trevor D. Lohrey, Dahlia D. An, Rebecca J. Abergel